MAP2K7 and melanoma: Hu-Lieskovian et al. [55] investigated in vivo the treatment efficacy of anti-CTLA4 antibodies with the simultaneous administration of BRAF inhibitors and/or MEK inhibitors in melanoma patients with the BRAF (V600E) mutation.